PET/MR scans demonstrated a higher capacity for mapping recurrent prostate cancer by finding more areas of prostate cancer metastases than hybrid PET/CT imaging, according to the results of a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 Annual Meeting in Vancouver.

Amyloid plaque burden has been linked with hypometabolism of neurons in areas of the brain associated with Alzheimer’s disease, according to the results of a study presented at the Society of Nuclear Medicine and Molecular Imaging’s 2013 annual meeting in Vancouver.

Ischemic small-vessel disease (SVD) wreaks havoc on the brain’s executive function and processing speed and is thought to be caused by gradual disconnects in the white matter tract and other cortical tissues leading to long-term cognitive impairment and disability. However, diffusion changes in apparently healthy tissues can reveal tell-tale signs of impending cognitive decline, according to a study published February 19 in the Annals of Neurology.

With a host of guidelines for tumor response presented by the now well known Response Evaluation Criteria in Solid Tumors (RECIST) and PET Response Criteria in Solid Tumors (PERCIST), clinicians need to know that not all parameters are alike for predicting patient survival. Case in point, metabolic volume and lesion glycolysis using F-18 FDG PET has been found to be more predictive of survival in patients with metastatic colorectal tumors treated with radioembolization than standardized uptake guidelines, according to a study published May 31 in the Journal of Nuclear Medicine.

PETNET Solutions, a wholly owned subsidiary of Siemens Medical Solutions USA, Inc., will soon begin manufacturing Eli Lilly and Company’s AmyvidTM (Florbetapir (18F)) radiopharmaceutical in the United Kingdom, as well as in Spain and France, after signing a manufacturing services agreement with Eli Lilly and Company. Siemens’ PETNET Solutions will function as a contract manufacturer for Lilly after Lilly’s diagnostic radiopharmaceutical received marketing authorisation from the European Commission in early 2013.

IBA (Ion Beam Applications S.A.), the global high-tech leader in next generation radiation therapy and diagnostics for the treatment of cancer, is pleased to announce that today 60 radiation therapy leaders travelled to Belgium to discover the first Proteus®ONE in factory.

Out of a range of mathematical methods for managing pulmonary nodules with FDG PET/CT, one quantitative CT technique takes the lead--dynamic area-detector CT analyzed using the dual-input maximum slope method, according to a study published May 22 in the American Journal of Roentgenology.

Many studies have maintained that the most advanced SPECT cameras can significantly reduce patient dose, but what about medical staff? A new protocol of myocardial perfusion SPECT imaging combines state-of-the-art detector technology, image reconstruction and stress-only imaging, all precipitating an up to 60 percent drop in radiation exposure to healthcare workers, according to a study published May 30 in the Journal of Nuclear Medicine.